August 2023 Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma – Cancers 2021
August 2023 Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma – Blood Adv. 2020
June 2023 IMWG consensus criteria for response and minimal residual disease assessment in Multiple Myeloma – Lancet Oncol. 2016
June 2023 Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma – Front Oncol. 2020
June 2023 Making clinical decisions based on measurable residual disease improves the outcome in Multiple Myeloma – J Hematol Oncol. 2021
June 2023 Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration – Clin Cancer Res. 2021
June 2023 Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications – Front Oncol. 2022
June 2023 Extramedullary disease in multiple myeloma: a systematic literature review – Blood Cancer J. 2022
June 2023 Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure! – Journal of Clinical Oncology, 2022